Appropriate imaging for breast cancer screening in special populations

Institute for Clinical and Economic Review (ICER)
Record ID 32015000928
English
Authors' recommendations: Based on the deliberations of key health outcomes, the committee decided that it had the most complete information: a comprehensive and current evidence report, public comments, and state agency utilization information. The committee concluded that the evidence is sufficient and to cover digital breast tomosynthesis (DBT) for breast cancer screening for woman aged 40 to 74 who are candidates for screening mammography. The committee concluded that the available evidence is not sufficient to support coverage for magnetic resonance imaging (MRI), Hand Held Ultrasound (HHUS) and Automated Breast Ultrasound (ABUS) for supplementary screening following mammography. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable. Based on these findings, the committee voted to cover DBT for woman aged 40 to 74 who are candidates for screening mammography. Separately, the committee voted to not cover MRI, HHUS and ABUS for supplementary screening following mammography.
Details
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Image Processing, Computer-Assisted
  • Sensitivity and Specificity
  • Contrast Media
  • Elasticity Imaging Techniques
  • Imaging, Three-Dimensional
  • Mammography
  • Ultrasonography, Mammary
Contact
Organisation Name: Institute for Clinical and Economic Review
Contact Address: 101 Merrimac St., 10th FL., Boston MA, USA 02114, Tel: (617) 724-4445 , Fax: (617) 726-9414
Contact Name: info@icer-review.org
Contact Email: info@icer-review.org
Copyright: Institute for Clinical and Economic Review (ICER)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.